Cwm LLC purchased a new position in LifeMD, Inc. (NASDAQ:LFMD – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,350 shares of the company’s stock, valued at approximately $59,000.
Other hedge funds also recently bought and sold shares of the company. Quest Partners LLC bought a new position in LifeMD in the 2nd quarter worth about $31,000. EntryPoint Capital LLC bought a new position in LifeMD in the 1st quarter worth about $89,000. Los Angeles Capital Management LLC bought a new position in LifeMD in the 2nd quarter worth about $88,000. SG Americas Securities LLC bought a new position in LifeMD in the 3rd quarter worth about $70,000. Finally, The Manufacturers Life Insurance Company bought a new position in LifeMD in the 2nd quarter worth about $93,000. Institutional investors own 35.52% of the company’s stock.
LifeMD Price Performance
Shares of NASDAQ:LFMD opened at $4.29 on Monday. The firm’s 50 day moving average price is $4.95 and its 200-day moving average price is $6.91. LifeMD, Inc. has a twelve month low of $4.10 and a twelve month high of $12.88. The company has a quick ratio of 0.83, a current ratio of 0.87 and a debt-to-equity ratio of 10.83. The stock has a market capitalization of $179.14 million, a PE ratio of -5.80 and a beta of 1.18.
Analysts Set New Price Targets
LFMD has been the subject of a number of recent analyst reports. B. Riley initiated coverage on LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th. Finally, KeyCorp decreased their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, LifeMD has a consensus rating of “Buy” and a consensus target price of $12.00.
Check Out Our Latest Stock Report on LFMD
LifeMD Company Profile
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Recommended Stories
- Five stocks we like better than LifeMD
- Conference Calls and Individual Investors
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding LFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeMD, Inc. (NASDAQ:LFMD – Free Report).
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.